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Abstract Receptor-bound urokinase is likely to be a crucial determinant in both tumor invasion and angiogenesis. We report here that a yeast-derived 
genetic conjugate between human serum albumin and the 1-135 N-terminal residues of urokinase (u-PA) competitively inhibits the binding of 
exogenous and endogenous u-PA to its cell-anchored receptor (u-PAR). This hybrid molecule (ATF-HSA) also inhibits in vitro pro-urokinase- 
dependent plasminogen activation in the presence of u-PAR bearing cells. These effects are probably responsible for the observed in vitro inhibition 
of tumor cell invasion in a reconstituted basement membrane extract (Matrigel). 
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1. Introduction 
The urokinase receptor (u-PAR), a 55 kDa glycoprotein 
linked to the cell membrane by a glycosylphosphatidylinositol 
anchor, plays a central role in cell migration and tissue remod- 
elling [1,2]. For example, migrating cells distribute u-PAR se- 
lectively on the leading edge of the membranes, and thus con- 
centrate u-PA secreted either by themselves or by neighboring 
stromal cells [3,4]. Importantly, u-PA binding to its specific 
receptor greatly potentiates plasminogen activation on the cell 
surface [5]. Generated plasmin is a wide range serine protease 
which can directly degrade some of the components of the 
extracellular matrix such as fibronectin or laminin, but can also 
promote local degradation of the stroma by its ability to con- 
vert inactive zymogens into active metalloproteinases [6]. Fur- 
thermore, the u-PA/u-PAR is also likely involved in neovascu- 
larization, an essential process for tumor cell proliferation and 
metastasis [7,8]. 
Therefore, therapeutic molecules aimed at disrupting the u- 
PA/u-PAR interaction might be effective in anticancer therapy 
by targeting both tumor cell invasiveness and angiogenesis. For 
example, monoclonal antibodies directed against u-PA or 
u-PAR, or small peptides derived from the receptor-binding 
domain (epidermal growth factor-like domain) of u-PA have 
proven to be effective in decreasing the invasiveness of cancer 
cells in vitro [9-l 11. In addition, Wilhem et al. recently reported 
that a soluble form of u-PAR consisting of its 277 aminotermi- 
nal residues could be secreted by CHO cells and that this re- 
combinant molecule could inhibit both the proliferation and 
the in vitro invasion of cells derived from a human ovarian 
cancer [12]. Most importantly, with the view of designing a 
long-lasting antagonist of the u-PA/u-PAR interaction, 
Crowley et al. constructed a chimeric molecule consisting of the 
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cell binding domain of u-PA genetically linked to the constant 
region of an immunoglobulin [13]. This hybrid molecule, re- 
ferred to as an immunoadhesin [14,151, was efficient in inhibit- 
ing the dissemination of human tumor cells in a metastasis 
experimental model. 
Another way to enhance the bioavailability of an otherwise 
unstable peptide is based on its genetic fusion to human serum 
albumin [16]. The pharmacokinetic issue of bioavailability is 
important because antiproteolytic strategies aimed at control- 
ling disease progression will probably require long-term treat- 
ment before any clinical benefit is apparent. As a first step to 
study the efficacy of a long-term displacement of u-PA from its 
cell surface receptor during the metastatic process, we designed 
a genetic conjugate between human serum albumin (HSA) and 
the receptor binding, non-catalytic aminoterminal fragment of 
u-PA (ATF) [17]. In this work we report the construction and 
the isolation of this chimeric molecule which can be efficiently 
secreted by Kluyveromyces yeasts and purified and its efficacity 
on cell biology. ATF-HSA is a potent antagonist of the u-PA/ 
u-PAR interaction on the surface of cancer cells and is a prom- 
ising agent as indicated by its remarkable in vitro efficacy in 
inhibiting cancer cell invasiveness. The physiological implica- 
tions of this effect are discussed. 
2. Materials and methods 
2.1. ATF-HSA protein expression and purification 
The gene encoding the ATF-HSA genetic conjugate (748 residues) 
was generated by PCR amplification of the HSA and the human u-PA 
cDNAs. Briefly, this composite gene is contained within a Hind111 
restriction fragment hat can be described from its 5’ to 3’ end by the 
succession of: (i) a HindIII-BgZII fragment comprising the 22 nucleo- 
tides (nt) of the 5’ untranslated region (from the CAP site to the trans- 
lation initiation codon) of the Saccharomyces cerevisiae PGK gene, 
immediately followed by a 72 nt sequence ncoding the 24-residue HSA 
proper region. This secretion signal is known to be fully functional in 
Kluyveromyces lactis [16,18] due to the presence. of KEXl maturase 
activity (the homologue of the KEX2 activity of S. cerevhiae); 
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(ii) genetically linked to a BamHI-AhaII restriction fragment encoding 
the first 135 N-terminal residues of mature human u-PA (ATF), imme- 
diately followed by a four Gly amino acid spacer; (iii) genetically linked 
to an AhaII-Hind111 restriction fragment coding for the 585 residues 
of mature HSA. This Hind111 fragment was then cloned in an E. coli-K. 
Zactis shuttle vector to generate plasmid pYG1477 (Fig. 1). This plasmid 
is isogenic to plasmid pYGl07 except that the Hind111 fragment en- 
codes the ATF-HSA gene instead of HSA [18]. Plasmid pYG1477 is 
thus a multicopy pKDl-derived expression plasmid which can stably 
propagate in K&y;eromyces yeasts [19,20]. It was transferred in K Zac- 
tis strain MW98-8C (a cir“ strain kindly supplied by H. Fukuhara, 
Orsay, France), and transformants were se&ted at-28“C on YPD 
(yeast extract l%, bactopeptone 2%, glucose 2%) plates containing 200 
mg/l of Geneticin (G418). The transformants were then grown in shake 
flasks for 72 h in YPL (same composition as YPD except that 2% 
lactose was used instead of glucose) to allow for maximal expression 
of the ATF-HSA protein from the LAC4 promoter of pYG1477. SDS- 
PAGE analysis of the culture supernatants indicated that the hybrid 
protein (80 kDa) is by far the most abundant protein, and is therefore 
easily recovered and puri6ed. For that purpose, the cells were sedi- 
mented by centrifugation and the supernatant was diaflltrated against 
a Tris 50 mM DH 7.3 buffer. It was then concentrated using a MINI- 
ULTRASETTE device (Filtron Tee. Corp.) equipped with-a 10 kDa 
cut-off membrane, and loaded on a 7 ml anion exchange D Zephyr 
column (Sepracor) from which the chimeric protein was eluted with a 
O-l M NaCl gradient. Fractions containing the protein were then 
pooled, dialyzed and passed on a pseudo-athnity Trisacryl Blue column 
(Sepracor) from which it was eluted by a one step 3.5 M NaCl gradient. 
After extensive dialysis against pure water, the protein was freeze-dried 
and stored at -70°C. Purity was estimated by SDS-PAGE analysis. 
2.2. Cell calrare 
Human breast-adenocarcinoma cell line MDA-MB-231 was cultured 
in DMEM medium containing 10% FCS, while monoblast cell line 
U937 was cultured in RPMI-1640 medium containing 10% FCS as 
described [21,22]. 
2.3. Inhibition of u-PA binding to u-PAR 
Recombinant Single chain-urokinase @u-PA, provided by Grunen- 
thal GmbH, Aachen, Germany) was radioiodinated by the chloramine 
T procedure [23]. U937 cells were used in the binding assay. Cell-bound 
bla 
Fig. 1. Construction of the ATF-HSA expression plasmid. pYG1477 
is a multi-copy pKDl-derived plasmid which can stably propagate in 
R Zactis yeast. Secretion of the ATF-HSA hybrid is directed by the 
prepro secretion leader from HSA. Relevant restriction sites are indi- 
cated: E, EcoRI; S, SaZI; H, HindIII; A, AhaII. Abreviations used: 
P, K. Zactis LAC4 promoter; T, S. cerevisiae PGK transcription termi- 
nator; A, B, and C refer to the three open reading frames from plasmid 
pKD1, and IR to its inverted repeats. bla and aph refer to the selective 
markers allowing selection of E. coli transformants with ampicillin and 
K Zactis transformants with geneticin, respectively. 
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Fig. 2. Inhibition of [‘251]scu-PA binding to U937 cells. 2 nM of [‘251]scu- 
PAwas added to the acid-eluted U937 cell suspension with or without 
ATF-HSA, rHSA or unlabeled scu-PA at the indicated concentrations. 
After 2 h incubation at 4°C with gentle agitation, the cells were placed 
on a 20% sucrose-PBS solution and centrifuged to remove unbound 
[‘251]scu-PA. Cell-bound [‘251]scu-PA was counted with a gamma 
counter. 
urokinase was first removed by a 3 min exposure at room temperature 
to a 0.05 M glycine-HCl @H 3.0)/0.1 M NaCl solution. The cell suspen- 
sion was then neutralized by addition of 0.2 volumes of a 0.5 M 
HEPES@H 7.5)/0.1 M NaCl solution, and centrifuged. Cells were re- 
suspended at a concentration of 2.5 x 106/ml in PBS containing 0.5% 
bovine serum albumin (BSA), and incubated for 2 h at 4°C with 2 nM 
[125L]scu-PA together with different concentrations of the ATF-HSA 
genetic onjugate, recombinant human serum albumin (rHSA) (Rhone 
Poulenc Rorer) or unlabelled scu-PA with gentle agitation. An uroki- 
nase inhibitory tripeptide Glu-Gly-Arg-Ketone (0.1 mM) and plasmin 
inhibitor aprotinin (100 nM) were included in the incubation buffer to 
avoid any enzymatic reaction. 100 ml aliquots of the cell suspensions 
were then layered on 0.5 ml of a 20% sucrose-PBS buffer, and the cells 
were sedimented for 5 min at 12,000 x g. The radioactivity associated 
with the cells was counted in a gamma counter. All tests were performed 
in triplicate. 
2.4. Zymogram assays 
Zvmography was performed essentially as described [8] with a mix- ____.. 
ture-of l-&of an 8% commercial instant nonfat dry milk solution, 1.5 
ml of PBS (with 0.9 mM Ca*’ and 1 mM Ma?. 1.5 ml of a 2.5% 2~2~ 
solution in water, and 40 ~1 of a 4 mg/ml plaiminogen solution in a-66 
mm culture dish. The gel was formed in the absence or presence of 
1 mM amiloride (Sigma, USA), a specific inhibitor of u-PA. After 
overnight culture in the presence or the absence of different concentra- 
tions of ATF-HSA or recombinant ATF (kindly given by Prof. M. 
Soria, Milano, Italy), 25 x 10’ washed U937 or MDA-MB-231 cells 
were laid down onto the gels. After a 4 h incubation at 37°C the 
zymogram was then analyzed for areas of lysis. 
2.5. Inhibition of pZasminogen activation in the presence of cell- 
associated u-PAR 
lo6 U937 or MDA-MB-231 cells were first incubated for 3 min in a 
0.05 M glycine-HCl(pH 3.0)/O. 1M NaCl solution, as described above. 
Followina neutralization, the cells were incubated with 0.08 nM of ._ _-
scu-PA as 37°C in the presence of different concentrations of ATF- 
HSA for 10 min. Glu-plasminogen at 0.4 PM (Kabi Vitrum, Sweden) 
was then added and the mixture was incubated at 37’C for different ___-_
time periods to generate plasmin. At the end of the incubation period. 
u-PA-activity w-as neutralized by the tripeptide Glu-Gly-Arg-ketone 
(0.1 mM: kindly nrovided by Pr. Liinen, Leuven, Belgium), and plaqmin _-____ 
generated was-evaluated by its amidolytic activity on. the plasmin- 
sensitive chromogenic substrate S-2251 (Kabi Vitrum, Sweden). The 
paranitoanilin released from the substrate was measured by its absorb- 
ance at 405 nm. Plasmin generation was calculated by comparison with 
a standard curve established with purified plasmin (Kabi Vitrum, Swe- 
den). 
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2.6. Cell invadon assay 
The assay was performed essentially as described [24]. Briefly, 6.5 
mm* polycarbonate iilters of 1.2~pm pore size (transwell, Costar) were 
coated with 50 ,ug of basement membrane xtracts (kindly provided by 
Dr. Foidart, Liege, Belgium) and dried. The lower chambers of the 
transwell units were filled with fibroblast conditioned medium supple- 
mented with 2 mg/ml of BSA, while the upper chambers of the units 
were seeded with 2 x 10’ MDA-MB-231 cells in serum free DMEM 
culture medium containing 0.2 mg/ml of BSA. The inhibitors were then 
added into the upper chambers and the transwell units were incubated 
for 24 h in a culture chamber. The cells and the matrigel on the upper 
side of the filters were then carefully removed so that the cells which 
traveled through the matrigel and adhered on the inferior side of the 
filters could be stained by May-Grtlnwald and Giemsa coloration, and 
counted with a microscope. 
3. Results and discusion 
Previous work first indicated that u-PA binds to its receptor 
via residues 12-32 of its EGF domain [17]. ATF, a fragment 
of u-PA composed of the EGF domain followed by the kringle 
domain of u-PA, is a more efficient antagonist than the 12-32 
peptide [ 17, and data not shown]. However, the purification of 
natural ATF is time-consuming and yield limited quantity. In 
addition, the in vivo unstability of small polypeptides in general 
renders the ATF unsuitable for the use in vivo experiments. 
Therefore, we have constructed a genetic conjugate composed 
of the 135 N-terminal residues of u-PA associated to HSA. 
HSA was chosen as a pharmacological carrier for the following 
reasons: (i) it is a long-lasting neutral carrier which can be 
secreted by Kluyveromycesyeasts to very high levels [18], (ii) it 
can escape the vascular compartment allowing access to cancer 
tissue, and (iii) it has previously been shown to increase the 
half-life of a 179-residue peptide in rabbits by 140-fold [16]. The 
composite ATF-HSA gene is expressed from the LAG4 pro- 
moter of pYG1477, a multicopy pKDl-derived expression plas- 
mid (Fig. 1) which can be stably propagated in Khyveromyces 
yeasts (data not shown). SDS-PAGE analysis of the culture 
supematants indicated that the hybrid protein (80 kDa) is by 
far the most abundant protein (120/150 mg/l in shake-flasks 
cultures), enabling easy recovery and characterization. After 
1 ntvl 
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isolation the purity of the chimeric molecule was more than 
90%. 
To evaluate the biological activity of this chimeric molecule, 
we first tested its ability to inhibit exogenous u-PA binding to 
U937 cells which are known to express abundant u-PAR on 
their cell surface. In this assay, cell bound u-PA was first eluted 
from the cell surface by an acid treatment. The purified ATF- 
HSA fusion protein was then compared with recombinant scu- 
PA for its ability to compete for the binding of [‘IsI]scu-PA to 
the cell surface. The results show that 50% inhibition of the 
binding of labeled scu-PA (2 nM) required 3.1 nM scu-PA, or 
4.2 nM ATF-HSA (Fig. 2), while no inhibition was observed 
with the recombinant HSA as control. We therefore concluded 
that ATF-HSA is a potent inhibitor of scu-PA binding to 
u-PAR. These results also indicate that the ATF moiety of the 
hybrid is fully accessible to the cell surface u-PAR. 
Because binding of u-PA to its receptor may occur in an 
autocrine fashion in cells which synthesize both u-PA and 
u-PAR (especially in endothelial cells and some cancer cells 
such as U937 or MDA-MB-231 cells) and consequently exhibit 
high endogenous u-PA activity on their surface, we tested in a 
second time if ATF-HSA could inhibit the binding of en- 
dogenous u-PA. For this purpose, MDA-MB-231 cells were 
cultured overnight in the presence of ATF-HSA at different 
concentrations, and u-PA activity was then measured in a zy- 
mogram assay [8]. As shown in Fig. 3, the ATF-HSA hybrid 
protein can inhibit endogenous u-PA activity in a dose-depend- 
ent manner. In the presence of amiloride, lysis was totally 
inhibited (not shown) demonstrating that lysis was only de- 
pendent on u-PA. Moreover, since the hybrid-mediated inhibi- 
tion was highly efficient when compared to ATF, we again 
concluded that genetic coupling had not significantly reduced 
the ability of the ATF moiety to interact with u-PAR. Identical 
results were also obtained with U937 cells (data not shown). 
Taken together, these experiments clearly demonstrate that our 
fusion protein efficiently competes with both endogenous and 
exogenous u-PA for binding to u-PAR. 
It has previously been shown that plasminogen activation by 
scu-PA was greatly enhanced when both molecules were bound 
1OnM 1OOnM 1OOOnM 
A ,TF-HSA 
ATF 
HSA 
Fig. 3. Inhibition of endogenous u-PA binding to MDA-MB-231 cells. The cells were incubated for 16 h with the indicated concentrations of 
ATF-HSA, rATF or rHSA. The cells were then suspended with 0.05% EDTA solution, washed 3 times with culture medium and 2.5 x 10’ cells of 
each sample were applied to a thin layer of agar containing casein and plasminogen. After 4 h incubation at 37*C, the agar gel was photographed 
under dark-field illumination. 
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Fig. 4. Inhibition of plasminogen activation in the presence of cell-associated u-PAR. lo6 acid-eluted U937 or MDA-MB-231 cells were mixed with 
0.08 nM scu-PA with or without the indicated concentrations of ATF-HSA or control rHSA. After 10 min, glu-plasminogen was added into the 
mixture, and the reaction was allowed to proceed until the addition of 0.1 mM of the u-PA inhibitor Glu-Gly-Arg-ketone at the indicated times. 
The cells were then removed and the concentration of generated plasmin was assayed in the presence of plasmin sensitive substrate S-2251. 
to their respective surface receptors [5]. The neutralization of 
this u-PAR potentiating effect by the ATF-HSA hybrid was 
therefore investigated. We first confirmed that plasmin genera- 
tion was considerably enhanced when U937 cells or MDA-MB- 
231 cells were added to a mixture of plasminogen and scu-PA 
(Fig. 4). Interestingly, we found that this enhancement was also 
inhibited in a dose-dependent manner by the addition of ATF- 
HSA. This effect is specitic to the ATF moiety of the hybrid 
since rHSA again had no effect in this assay. 
The construction of this ATF-HSA by genetic engineering 
technique will facilitate a series of in vivo studies. The an- 
time&static effect of in vivo administration of uPAR antagonist 
is mostly expected and proven effective in some experimental 
models [ 11,131 The ability of the ATF-HSA molecule to inhibit 
tumor cell invasiveness in vitro on a reconstituted extracellular 
matrix (Matrigel)was checked, and we found that the invasion of 
MDA-MB-231 cells was inhibited by approximately 50% at 120 
nM, and by 80% at 750 nM. Its anticancer effect remains to be 
tested in vivo. Furthermore, since the expression of uPAR is not 
limited to cancer cells, other potential applications such as 
anti-inflammatory or anti-angiogenic effects as well as relevant 
side effects could also be expected. Thus, the construction of this 
molecule with satisfying pharmaceutical properties is a critical 
step of the work aimed to explore the usefulness of uPA : uPAR 
antagonist in a number of clinical applications. 
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